Healthcare Sector Poised for "Davis Double Play",Guotai CSI Medical Service ETF (159828) Surges Nearly 3% in Morning Trading, Aiming for Fifth Consecutive Gain

NewTimeSpace News, as of 09:43 on January 14, 2026,  Medical ETF (159828) rose 2.91%, aiming for its fifth consecutive gain, with the latest price at RMB 0.5.

Looking at a longer timeframe, as of January 13, 2026, Medical ETF has accumulated a 6.89% gain over the past week. (The stocks listed above are index constituents only and do not constitute specific investment recommendations.)

In terms of liquidity, Medical ETF's intraday turnover ratio reached 1.72% with trading volume of RMB 38.0038 million. Looking at the broader timeframe, as of January 13, the ETF's average daily trading volume over the past week was RMB 126 million.

Regarding scale, Medical ETF's latest assets under management reached RMB 2.171 billion, ranking 2nd among 4 comparable funds. (Data source: Wind)

Data shows leveraged funds continue to build positions. Medical ETF recorded a net purchase of RMB 3.2986 million through financing on the previous trading day, with the latest financing balance reaching RMB 65.0280 million. (Data source: Wind)

As of January 13, Medical ETF's NAV increased 27.38% over the past year.

In terms of return capability, as of January 13, 2026, since its inception, Medical ETF's highest monthly return reached 30.02%, the longest consecutive gain period lasted 5 months with a total gain of 23.83%, and the average return during positive months was 5.85%.

As of January 13, 2026, Medical ETF's 3-month annualized excess return over benchmark stood at 2.58%, ranking in the top 2 among 4 comparable funds.

Regarding drawdown, as of January 13, 2026, Medical ETF's maximum year-to-date drawdown was 0.00%, with a relative benchmark drawdown of 0.05%.

In terms of fees, Medical ETF's management fee rate is 0.50% and custody fee rate is 0.10%.

Medical ETF closely tracks the CSI Medical Index, which selects listed securities of pharmaceutical and healthcare companies engaged in medical devices, medical services, medical informatization, and other medical-related themes as index constituents to reflect the overall performance of medical-themed listed companies.

Zhongtai Securities stated that driven by multiple factors, demand for CRO/CDMO in the healthcare sector is gradually recovering. Combined with three consecutive years of supply-side consolidation, the sector is poised to welcome a "Davis Double Play" where both earnings and valuations improve simultaneously.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.